NEW YORK (GenomeWeb) – Indivumed and Helomics announced today that they have partnered to jointly offer products and services for cancer specimen research and clinical data analysis.
The companies said the deal will allow them to offer their customers access to Indivumed’s cancer database, biobank, and European research laboratory, as well as Helomics’ US-based analytical laboratory services for biospecimen analysis, CLIA testing capabilities, and bioinformatics platform.
Specific terms of the alliance were not disclosed.
The alliance comes less than a year after Pittsburgh-based Helomics completed its restructuring into a clinical contract research and clinical products organization. Hamburg, Germany-based Indivumed, meanwhile, has formed a number of alliances in recent months including ones with MedStar, Intermed, Regeneron, and Northwell Health.